SLGC logo

SomaLogic (SLGC) Stock

Profile

Full Name:

SomaLogic, Inc.

Sector:

Healthcare

Country:

United States

IPO:

23 April 2021

Indexes:

Not included

Description:

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Mar 28, 2024

Recent annual earnings:

Mar 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

05 Oct '23 Jefferies
Hold
25 Sept '23 Canaccord Genuity
Hold
29 Mar '23 TD Cowen
Outperform
29 Mar '23 Stifel
Buy
29 Mar '23 Canaccord Genuity
Buy
16 Aug '22 Cowen& Co.
Outperform
16 Aug '22 Cowen & Co.
Outperform
23 June '22 Cowen & Co.
Outperform
13 May '22 Canaccord Genuity
Buy
01 Feb '22 Stifel
Buy

Screeners with SLGC included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

SomaLogic Inc. (SLGC) Q3 2023 Earnings Call Transcript
SomaLogic Inc. (SLGC) Q3 2023 Earnings Call Transcript
SomaLogic Inc. (SLGC) Q3 2023 Earnings Call Transcript
SLGC
Seeking Alpha10 November 2023

SomaLogic Inc. (NASDAQ:SLGC ) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Noah Corin - IR, Gilmartin Group Adam Taich - Interim CEO Eliot Lurier - Interim Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Kyle Boucher - TD Cowen Operator Good afternoon, and welcome to SomaLogic's Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

Why SomaLogic Stock Dived by 10% on Wednesday
Why SomaLogic Stock Dived by 10% on Wednesday
Why SomaLogic Stock Dived by 10% on Wednesday
SLGC
The Motley Fool04 October 2023

It is merging with a peer in the next-generation medical tech field. This will be effected entirely in stock.

Why Shares of SomaLogic Are Up Tuesday
Why Shares of SomaLogic Are Up Tuesday
Why Shares of SomaLogic Are Up Tuesday
SLGC
The Motley Fool15 August 2023

SomaLogic makes life sciences tools. The company said it plans a launch of its SomaScan assay this year.

Somalogic, Inc. (SLGC) Q2 2023 Earnings Call Transcript
Somalogic, Inc. (SLGC) Q2 2023 Earnings Call Transcript
Somalogic, Inc. (SLGC) Q2 2023 Earnings Call Transcript
SLGC
Seeking Alpha14 August 2023

Somalogic, Inc. (NASDAQ:SLGC ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Marissa Bych - Group Investor Relations Adam Taich - Interim CEO Eliot Lurier - Interim CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Daniel Brennan - TD Cowen Daniel Arias - Stifel, Nicolaus & Company Brandon Couillard - Jefferies Operator Good afternoon, and welcome to SomaLogic's Second Quarter 2023 Earnings Conference Call. [Operator Instructions].

SomaLogic, Inc. (SLGC) Just Flashed Golden Cross Signal: Do You Buy?
SomaLogic, Inc. (SLGC) Just Flashed Golden Cross Signal: Do You Buy?
SomaLogic, Inc. (SLGC) Just Flashed Golden Cross Signal: Do You Buy?
SLGC
Zacks Investment Research07 June 2023

SomaLogic, Inc. (SLGC) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, SLGC's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

SomaLogic, Inc. (SLGC) Q1 2023 Earnings Call Transcript
SomaLogic, Inc. (SLGC) Q1 2023 Earnings Call Transcript
SomaLogic, Inc. (SLGC) Q1 2023 Earnings Call Transcript
SLGC
Seeking Alpha11 May 2023

SomaLogic, Inc. (NASDAQ:SLGC ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Adam Taich - Chief Executive Officer Shaun Blakeman - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Dan Arias - Stifel Financial Corp. Kyle Mikson - Canaccord Genuity Group Inc. Brandon Couillard - Jefferies Group LLC Operator Good afternoon, and welcome to SomaLogic's First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

SomaLogic, Inc. (SLGC) Reports Q1 Loss, Tops Revenue Estimates
SomaLogic, Inc. (SLGC) Reports Q1 Loss, Tops Revenue Estimates
SomaLogic, Inc. (SLGC) Reports Q1 Loss, Tops Revenue Estimates
SLGC
Zacks Investment Research11 May 2023

SomaLogic, Inc. (SLGC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.15 per share a year ago.

SomaLogic, Inc. (SLGC) Q4 2022 Earnings Call Transcript
SomaLogic, Inc. (SLGC) Q4 2022 Earnings Call Transcript
SomaLogic, Inc. (SLGC) Q4 2022 Earnings Call Transcript
SLGC
Seeking Alpha29 March 2023

SomaLogic, Inc. (NASDAQ:SLGC ) Q4 2022 Earnings Conference Call March 27, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Troy Cox - Chief Executive Officer Shaun Blakeman - Chief Financial Officer Adam Taich - EVP, Life Sciences Business Unit Conference Call Participants Dan Brennan - Cowen Kyle Mikson - Canaccord Genuity Operator Welcome to SomaLogic's Fourth Quarter and Full Year 2022 Earnings Call. All participants are in a listen-only mode.

FAQ

  • What is the primary business of SomaLogic?
  • What is the ticker symbol for SomaLogic?
  • Does SomaLogic pay dividends?
  • What sector is SomaLogic in?
  • What industry is SomaLogic in?
  • What country is SomaLogic based in?
  • When did SomaLogic go public?
  • Is SomaLogic in the S&P 500?
  • Is SomaLogic in the NASDAQ 100?
  • Is SomaLogic in the Dow Jones?
  • When was SomaLogic's last earnings report?
  • When does SomaLogic report earnings?
  • Should I buy SomaLogic stock now?

What is the primary business of SomaLogic?

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.

What is the ticker symbol for SomaLogic?

The ticker symbol for SomaLogic is NASDAQ:SLGC

Does SomaLogic pay dividends?

No, SomaLogic does not pay dividends

What sector is SomaLogic in?

SomaLogic is in the Healthcare sector

What industry is SomaLogic in?

SomaLogic is in the Health Information Services industry

What country is SomaLogic based in?

SomaLogic is headquartered in United States

When did SomaLogic go public?

SomaLogic's initial public offering (IPO) was on 23 April 2021

Is SomaLogic in the S&P 500?

No, SomaLogic is not included in the S&P 500 index

Is SomaLogic in the NASDAQ 100?

No, SomaLogic is not included in the NASDAQ 100 index

Is SomaLogic in the Dow Jones?

No, SomaLogic is not included in the Dow Jones index

When was SomaLogic's last earnings report?

SomaLogic's most recent earnings report was on 28 March 2024

When does SomaLogic report earnings?

The date for SomaLogic's next earnings report has not been announced yet

Should I buy SomaLogic stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions